What diseases does durvalumab (durvalumab) mainly treat? How effective is it in treating tumors?

Durvalumab is an immune checkpoint inhibitor and an anti-PD-L1 monoclonal antibody. It mainly blocks the binding of the PD-L1 protein on the surface of tumor cells to the PD-1 receptor on the surface of T cells, thereby activating the immune system and enhancing the recognition and killing effect of immune cells on tumor cells. The drug is currently used to treat several types of cancer, including non-small cell lung cancer (NSCLC), bladder cancer and other tumors. As an immunotherapy drug, durvalumab has received widespread attention for its clinical effects and application prospects.

Durvalumab is currently approved for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), particularly those with high PD-L1 expression. In these patients, durvalumab significantly improved progression-free survival (PFS) and overall survival (OS). Additionally, durvalumab is approved for the treatment of locally advanced or metastatic urothelial carcinoma (bladder cancer), particularly in patients who cannot receive platinum-based chemotherapy. The drug has become a standard treatment for some cancers, and its efficacy has been proven in multiple clinical trials.

In the treatment of non-small cell lung cancer, durvalumab has shown significant efficacy, especially when combined with chemotherapy drugs. Especially for patients with high PD-L1 expression, durvalumab can effectively improve their immune response and prolong their survival. In multiple pivotal Phase III clinical trials, durvalumab significantly reduced the risk of tumor progression and enhanced patients' treatment response compared with traditional chemotherapy. In addition, durvalumab is also used to treat some other types of cancer, such as bladder cancer. Its efficacy is similar to its application in lung cancer, providing patients with more treatment options.
Like most immunotherapy drugs, durvalumab has certain side effects. Common adverse reactions include fatigue, decreased appetite, nausea, rash, and immune-mediated side effects such as pneumonia, hepatitis, colitis, etc. Although these side effects are relatively mild, some patients may experience serious immune-related adverse reactions due to activation of the immune system. Therefore, patients need to be closely monitored under the guidance of doctors when using durvalumab to detect and deal with possible immune-related side effects in a timely manner.
Reference: https://www.imfinzi.com/